MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

On September11, 2017, Marinus Pharmaceuticals,Inc. (the “Company”) conducted an investor conference call and webcast. A copy of the slides presented during that call is submitted as Exhibit99.1 to this Current Report on Form8-K and is incorporated by reference in this Item 7.01 as though fully set forth herein.

Item 8.01. Other Events.

On September11, 2017, the Company issued a press release announcing top-line results from a Phase 2 open-label study in patients with CDKL5 disorder. A copy of the press release is filed as Exhibit99.2 to this Current Report on Form8-K and is incorporated by reference in this Item 8.01 as though fully set forth herein.

Item 9.01. Financial Statements and Exhibits.


MARINUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a17-21553_1ex99d1.htm EX-99.1 Exhibit 99.1 Mindful Innovation Phase 2 Clinical Study Evaluating Ganaxolone in Children with CDKL5 Disorder September 11,…
To view the full exhibit click here

About MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.